This promising approach, including monoclonal antibodies for the therapy of melanoma, targets the programmed cell death protein 1 receptor (PD-1) and its ligand (PDL-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and lymphocyte-activation gene 3 (LAG-3) in order to enable the tumor-silenced immune response [23]. This evidence concerns the gene CTLA4 and melanoma.